Jason Goldman
Infectious Disease · Seattle, WANPI 1740436609
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Gilead accounts for 69.7% of it on its own, with 5 other manufacturers making up the rest. Among infectious disease clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 50 payments — averaging $1159.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$40K
- Lilly USA, LLC$9K
- Eli Lilly$4K
- Merck$3K
- Invivyd Inc$2K
- Angiodynamics, Inc.$123
Across 330 payments — averaging $18,711 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$3.2M
- Eli Lilly$1.3M
- Merck$741K
- Regeneron$601K
- Adaptive Biotechnologies Corporation$183K
- Astellas Pharma Global Development$96K
- plus $48K from 2 others
What the payments were for
- Consulting fees$22,95740%
- Speaking & faculty fees$29,57551%
- Travel & lodging$4,3848%
- Food & beverage$1,0442%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 42 | $40,417 |
| Lilly USA, LLC | 3 | $8,925 |
| Eli Lilly | 1 | $3,750 |
| Merck | 2 | $3,120 |
| Invivyd Inc | 1 | $1,625 |
| Angiodynamics, Inc. | 1 | $123 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$57,960 in reported general payments places this provider in the 95th percentile of 186 infectious disease providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 70 | $286,124 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 22 | $84,089 |
| JulucaDolutegravir/Rilpivirine | 23 | $81,307 |
| DescovyEmtricitabine/Tenofov Alafenam | 33 | $72,911 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 13 | $71,059 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 12 | $41,637 |
| TivicayDolutegravir Sodium | 12 | $25,844 |
| VemlidyTenofovir Alafenamide | 12 | $15,649 |
| Doxycycline Hyclate | 35 | $1,126 |
| Methenamine Hippurate | 17 | $996 |
| Cephalexin | 17 | $328 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy, Vemlidy | $40,417 | $458,774137 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 186 infectious disease providers in Washington.
Other infectious disease in Seattle
- Warren DingesSeattle$173K
- Paul DrainSeattle$149K
- Corey CasperSeattle$115K
- Anna WaldSeattle$103K
- Jim BoonyaratanakornkitSeattle$62K
- Michael BoeckhSeattle$59K
- Connie CelumSeattle$57K
- Hyang KimSeattle$51K
- Ferric FangSeattle$49K
- Heidi CraneSeattle$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.